复星凯特生物科技有限公司（简称“复星凯特”）于2017年初在上海张江高科技园区成立，为上海复星医药集团与美国 Kite（吉利德科学旗下公司）的合营企业，目前注册资本为20900万美元，中美双方持股比例各为50%。复星凯特以“专注治愈 点亮人生”为使命，以“成为最有价值的细胞和基因疗法引领者”为愿景，专注于肿瘤细胞治疗产品的研发、产业化和商业化发展，造福中国患者。
复星凯特成立以来，仅用4年时间就完成了第一款CAR-T细胞治疗药物阿基仑赛注射液（商品名：奕凯达®）的全面技术转让及快速上市，于2021年6月成为中国首个获批上市的细胞治疗类产品，用于治疗既往接受二线或以上系统治疗后复发或难治性大B细胞淋巴瘤成人患者。截至2023年4月，奕凯达®已惠及400多位肿瘤患者，纳入80多款省市惠民保项目。该产品的二线适应症（用于治疗一线免疫化疗无效或在一线免疫化疗后12个月内复发的成人大B细胞淋巴瘤）的免临床附条件上市申报已获得国家药监局（NMPA）正式受理并纳入优先审评。奕凯达的第二个适应症（用于治疗接受过二线或以上系统治疗后复发或难治性惰性非霍奇金淋巴瘤成人患者）已获批临床并被纳入突破性治疗药物品种。公司第二款CAR-T细胞治疗药物FKC889的两个适应症（①针对既往接受过二线及以上治疗后复发或难治性套细胞淋巴瘤，②针对治疗复发或难治性成人前体B细胞急性淋巴细胞白血病）分别于2022年3月和12月获批临床。
公司近10000平方米的CAR-T产业化生产基地已于2019年12月在张江创新药产业基地建成并正式启用。此外，公司拥有2000平米的细胞治疗研发中心和创新人才团队，通过自主创新和国际合作，专注CAR-T早期研发和临床循证阶段的项目，打造可持续的创新研发管线。
Fosun Kite Biotechnology Co., Ltd. (referred to as "Fosun Kite") was established in early 2017 in Zhangjiang High tech Park, Shanghai. It is a joint venture between Shanghai Fosun Pharmaceutical Group and Kite Pharma (a subsidiary of Gilead Sciences) in the United States. Fosun Kite has a mission of "focusing on healing and illuminating life", and a vision of "becoming the most valuable leader in cell and gene therapy". It focuses on the research and development, industrialization, and commercialization of tumor cell therapy products, benefiting Chinese patients.
Since the establishment of Fosun Kite, in only 4 years’ time, it has launched the first CAR-T cell therapy product Yescarta (axicabtagene ciloleucel, Yikaida®) in China in June 2021. Yikaida®’s first indication is to treat adult patients with recurrent or refractory large B-cell lymphoma who have previously received second-line or above systemic treatment. As of April 2023, Yikaida® has treated over 400 cancer patients and has been listed in over 80 provincial and municipal welfare insurance reimbursement drug list. The second line indication of this product (used to treat adult large B-cell lymphoma that is ineffective in first-line immunochemotherapy or relapses within 12 months after first-line immunochemotherapy) has been officially accepted and was granted priority review by the National Drug Administration (NMPA). The second indication of Yikaida® (used to treat adult patients with recurrent or refractory indolent non Hodgkin's lymphoma after receiving second-line or above systemic treatment) has been approved for IND and was granted breakthrough treatment drug. Two indications of the company's second CAR-T cell therapy drug FKC889 (① for recurrent or refractory mantle cell lymphoma after previous second-line or above treatment, and ② for treating recurrent or refractory adult precursor B-cell acute lymphocytic leukemia) were approved for IND in March and December 2022, respectively.
The company's 10000 square meter CAR-T commercial manufacturing site was officially put into use in December 2019 at the Zhangjiang Innovative Pharmaceutical Industry Base. In addition, Fosun Kite has a 2000 square meter research and development center and an innovative talent team. Through independent innovation and international cooperation, Fosun Kite focuses on CAR-T research and development and clinical evidence-based projects, creating a sustainable innovative research and development pipeline.
www.fosunkitebio.com

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members.
The diverse membership base covers many of the world’s top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.
https://bayhelix.org/

eChinaHealth is a new business of eChinaChem in the field of medical health which is China's leading pharmaceutical and chemical B2B company. In 2019, eChinaHealth and the American Society of Clinical Oncology (ASCO) signed the exclusive agency rights for ASCO official journals and magazines in Greater China, including the Journal of Clinical Oncology (JCO), Academic and business journals such as Journal of Oncology Practice (JOP), The ASCO Post (The ASCO Post), and more.
The ASCO Global Conference Abstracts and Data are the sole responsibility and operation by the Doctor Evidence (DRE) platform of the physician evidence company. eChinaHealth also signed the exclusive China agent for the DRE platform. Oncologists can use this AI-enabled platform to conduct in-depth queries on ASCO and other medical literature data, including advanced terminology search, concept identification, author analysis, and timeline analysis of authors' associations with other published literature. Advanced search capabilities allow users to search for comparisons and analyses across all calendar summaries, and present results and trends. The DRE platform includes summaries and data of all ASCO conferences over the past 20 years, enabling R & D personnel to track R & D trends and conduct longitudinal analysis and investigation of evolving data.
http://www.echinahealth.com/

CBA is an independent, non-political, not-for-profit professional organization led by its board of directors and executive committees. Currently, CBA has over 3000 registered individual members. Most of its members are from universities, research institutions, biopharmaceutical companies, law firms, venture capital firms, and government agencies. Over 80 percent of the CBA members have doctoral degrees.
CBA has grown to be a truly international organization, with members residing in the U.S., China, Europe, Canada, Singapore, Japan, Australia, and other countries and regions. CBA’s mission is to promote career advancement and collaboration among Chinese-American biopharmaceutical professionals, and to promote technology transfer and entrepreneurship, especially between the U.S. and China, as well as countries and regions in the Pacific Rim. Since its inception in 1995, CBA has been playing a prominent role in the Chinese and U.S. biopharmaceutical industries. Every year, CBA organizes a number of specially designed workshops, seminars, meetings, and networking events in both China and the U.S. To learn more about CBA, please visit
www.cba-usa.org.

Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) is a non-profit (501(c)(3)) professional organization founded in 2002 (www.sapa-gp.org). We strive to serve the rapidly growing pharmaceutical professional community in the Greater Philadelphia area. The Greater Philadelphia area is one of the major hubs for global pharmaceutical companies (e.g. BMS, GSK, Johnson & Johnson, Merck, Pfizer, Teva), biotech companies (e.g. Alliance Pharma, Frontage Laboratories, PuraCap, Shire) and academic institutions (e.g. University of Pennsylvania, Thomas Jefferson University, Temple University, Drexel University, Rowan University, Villanova University). Over past decades, SAPA-GP has established a broad member base and become the premier organization in the region for bridging the pharmaceutical and healthcare industries of China and the US.
Our Missions
• To promote pharmaceutical sciences and biotechnology
• To contribute to public health education by raising public awareness
• To facilitate scientific and business cooperation between US and China
• To foster career development of pharmaceutical professionals
Our members consist of
• Scientists, clinicians, and executives from pharmaceutical and biotech companies
• Students and postdoctoral fellows from academic institutions and universities
• Business and thought leaders from financial institutions and healthcare industries
Our Events
• Annual conference
• Scientific symposiums and webinars
• Business development workshops
• Career development workshops & Job fairs
• Professional training
www.cba-usa.org.

AAIH is a not-for-profit (501(c)(4)) founded in 2018 and formally launching in January 2019 (https://theaaih.org/). We are a global advocacy organization for the advancement and use of AI/ Machine Learning in healthcare to improve patients’ lives and create more efficient, sustainable, and accessible healthcare systems. Through investment, invention, and innovation in AI, the AAIH and our member organizations are creating novel interventions and product solutions that reduce failure rates and costs while improving quality across the entire healthcare spectrum. AAIH is a diverse member base that includes dedicated healthcare AI companies and organizations, as well as, those utilizing AI platforms for biomedical discovery, clinical research, diagnostics and devices, and precision medicine.
https://theaaih.org/